In This Section      
Print This Page

Search Results

A total of 38 matching records were found.

A087
Protocol AMC-087: Phase I Trial of Cabozantinib (XL184) for Advanced Solid Tumors in Persons with HIV Infection

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J0859
Hypofractionated Adaptive Image-Guided Radiation Therapy for Localized Adenocarcinoma of the Prostate

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Suburban Hospital

J11143
Multiparametric MRI for assessing radiotherapy treatment response of prostate cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J11157
Stereotactic Body Radiation Therapy and Short-Term Androgen Ablation for Intermediate-Risk, Localized, Adenocarcinoma of the Prostate

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Suburban Hospital

J1137
An Early Phase 1 Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Patients with Hepatic or Renal Dysfunction and Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1192
A Randomized Controlled Trial of Prostatak as Adjuvant to Up-Front Radiation Therapy for Localized Prostate Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1262
Understanding Mechanisms of Response and Resistance to Androgen-Directed Therapies in Men with Advanced Prostate Cancer Through Interrogation of Tumor Biopsies

Sites: Sibley Memorial Hospital, Johns Hopkins Kimmel Cancer Center in Baltimore

J1380
A biospecimen bank and study to understand genitourinary cancer and other benign urologic conditions.

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Johns Hopkins Bayview Medical Center, Sibley Memorial Hospital

J1409
Immune Evaluation Study of Sipuleucel-T in African American and non-African American Men with Castrate Resistant Prostate Cancer (Karmanos Cancer Institute protocol # 2013-108)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J14106
Non-invasive Detection of Cancer DNA in Blood and Urine

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J14146
A Randomized Phase II Study Comparing Bipolar Androgen Therapy vs. Enzalutamide in Asymptomatic Men with Castration Resistant Metastatic Prostate Cancer: The TRANSFORMER Trial (Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J1416
A Phase II Study to Determine Sequential Response to Bipolar Androgen Therapy (BAT) followed by Enzalutamide or Abiraterone Post-BAT in Men with Prostate Cancer Progressing on Combined Androgen Ablative Therapies RE-sensitizing with Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J1454
Phase II Randomized Placebo-Controlled Double-Blind Study of Salvage Radiation Therapy (SRT) Plus Placebo Versus SRT Plus Enzalutamide in Men with High-Risk PSA-Recurrent Prostate Cancer after Radical Prostatectomy (SALV-ENZA)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital, Suburban Hospital

J1480
My Pathway: MY PATHWAY: AN OPEN-LABEL PHASE IIA STUDY EVALUATING TRASTUZUMAB/PERTUZUMAB, ERLOTINIB, VEMURAFENIB/COBIMETINIB, VISMODEGIB, ALECTINIB, AND ATEZOLIZUMAB IN PATIENTS WHO HAVE ADVANCED SOLID TUMORS WITH MUTATIONS OR GENE EXPRESSION ABNORMALITIES PREDICTIVE OF RESPONSE TO ONE OF THESE AGENTS(Protocol Number: ML28897/PRO 02)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1504
Phase II Randomized, Placebo-Controlled Trial of PROSTVAC (PSA-TRICOM) in Patients with Clinically Localized Prostate Cancer Undergoing Active Surveillance (DCP Protocol #: UAZ2014-03-01)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Johns Hopkins Bayview Medical Center

J15106
A Randomized Phase 2 Trial of Ascorbic Acid in Combination with Docetaxel in Men with Metastatic Prostate Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J15119
Biomarker-Driven Phase-2 Study of Combined Immune Checkpoint Blockade for AR-V7–Expressing Metastatic Castration-Resistant Prostate Cancer (STARVE-PC)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J15122
A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Subjects with Metastatic Castrate-Resistant Prostate Cancer (Protocol Number: GS-US-350-1604)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J15180
Phase II Randomized Observation versus Stereotactic Ablative RadiatIon for OLigometastatic Prostate CancEr (ORIOLE) Trial

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Suburban Hospital, Sibley Memorial Hospital

J15188
EMBARK: A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy (Protocol Number: MDV3100-13)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J15203
Pilot Biomarker Study of Stereotactic Body Radiation Therapy for Prostate Cancer Oligometastases

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1522
A Randomized Phase 2 Study of Sipuleucel-T with or without Radium-223 in Men with Asymptomatic or Minimally Symptomatic Bone-Metastatic Castrate-Resistant Prostate Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J15221
A Phase 1 Study Evaluating Safety, Tolerability, and Preliminary Antitumor Activity of Entinostat and Nivolumab with or without Ipilimumab in Advanced Solid Tumors (NCI# 9844)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J15224
A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men with Biopsy Proven Low-Grade Prostate Cancer who are Candidates for Active Surveillance (proSPECT-AS) (Study Number: MIP-1404-3301)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1548
A Pilot Study of Dexamethasone Therapy Prior to Rechallenge with Enzalutamide in Men with Metastatic Castration-Resistant Prostate Cancer Dex EXTends Enza Response (The DEXTER Trial)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1557
Overcoming drug resistance in metastatic castration-resistant prostate cancer with novel combination of TGF-ß receptor inhibitor LY2157299 and enzalutamide: a randomized multi-site phase II study

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore, Sibley Memorial Hospital

J1581
STM-03: Phase I Study of Procaspase Activating Compound-1 (PAC-1) in the Treatment of Advanced Malignancies

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J16107
Partnering Around Cancer Clinical Trials (PACCT)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J16119
A PrOspective Phase 2/3 Multi-Center Study of 18F-DCFPyL PET/CT Imaging in Patients with PRostate Cancer: Examination of Diagnostic AccuracY (OSPREY) (Study Number: PyL 2301)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J16131
A Phase 1b Study of Enzalutamide plus CC-115 in Men with Castration-Resistant Prostate Cancer (CRPC) (Sponsor Protocol c15-160)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1615
A Phase 1 Study of Durvalumab and IPH2201 in Adult Subjects with Select Advanced Solid Tumors (Sponsor Protocol Number: D419NC00001)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1618
A phase II study of definitive therapy for newly diagnosed men with oligometastatic prostate cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1619
A Selective Androgen Receptor Modulator for Symptom Management in Prostate Cancer

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1630
Evaluation of the TULSA-PRO MRI-Guided Transurethral Ultrasound Prostate Ablation Device in Patients with Localized Prostate Cancer: a Prospective, Single-Arm, Pivotal Clinical Study (Protocol number: GCP-10100)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1674
An Open-Label Study of Rovalpituzumab Tesirine in Subjects with Delta-Like Protein 3-Expressing Advanced Solid Tumors (SCRX001-006)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1681
A Phase I Dose Escalating Trial of Mistletoe Extract in Patients with Advanced Solid Tumors

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1693
Neoadjuvant Enoblituzumab (MGA271) in Men with Localized Intermediate and High-Risk Prostate Cancer – a Pilot and Biomarker Study

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore

J1710
A Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza™) Versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal Agent and Have Homologous Recombination Repair Gene Mutations (PROfound)

Sites: Johns Hopkins Kimmel Cancer Center in Baltimore